Consequently, orexin receptor modulators, whether OX1R/OX2R agonists for hypoglycemia unawareness and type 1 diabetes or dual antagonists for nocturnal hyperglycemia in type 2 diabetes, will likely require sex-specific dosing, timing, or formulation. The gene discussed is HCRTR2; the disease is Hyperglycemia.